Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report-Reference-Cited by-同舟云学术

Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report

Published:2024-01 Issue: Volume:12 Page:
ISSN:2050-313X
Container-title:SAGE Open Medical Case Reports
language:en
Short-container-title:SAGE Open Medical Case Reports

Author:

Hashim Hashim Talib¹,Alhatemi Ahmed Qasim Mohammed²^ORCID,Aji Narjiss³,Shah Jaffer⁴

Affiliation:

1. College of Medicine, Warith Al Anbiyaa University, Karbala, Iraq

2. Department of Internal Medicine, Al Nasiriyah Teaching Hospital, Thi Qar, Iraq

3. College of Medicine, University of Drexel, Philadelphia, PA, USA

4. Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat, Rabat-Sale-Kenitra, Morocco

Abstract

This study examines the contraindications of gabapentin and Nucleo C.M.P Forte in metformin-controlled diabetic patients, focusing on their potential to induce hyperglycemia. A case report of a 65-year-old woman with type II diabetes is presented, demonstrating elevated blood glucose levels following the initiation of gabapentin and Nucleo C.M.P Forte. The literature review highlights limited data on gabapentin-induced hyperglycemia, with additional consideration of the potential effects of Nucleo C.M.P Forte. The study suggests modifying insulin therapy in diabetic patients taking gabapentin and calls for further research on this interaction.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/2050313X241265072

Reference14 articles.

1. Gabapentin

2. Gabapentin dosing in the treatment of epilepsy

3. Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™